We have recently commenced a new study funded and sponsored by Areteia Therapeutics and led at Nottingham by Dr Sherif Gonem.
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2).
Why is this study being done?
The purpose of this research study, which involves research, is to find out about the safety of dexpramipexole and how well it works for the treatment of severe asthma.
Dexpramipexole is an experimental medication, which is not approved by any health regulatory authority, including the United States (US) Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA). Dexpramipexole lowers the number of eosinophils in the blood, which are a type of white blood cell that plays a role in asthma.
Over the past several years, a few new drugs that lower eosinophils were approved by the US FDA, EMA and MHRA for the treatment of asthma (for example, mepolizumab/Nucala;
reslizumab/Cinqair; benralizumab/Fasenra).
All of these approved drugs are injected using a needle. Dexpramipexole comes in a tablet and is taken by mouth twice a day.